Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
-

Safety

  • Share Share this page
-

Serevent Diskus (salmeterol xinafoate inhalation powder)


Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- March 2008

 

The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary.


Summary View

 

Sections Modified Summary of Changes to Contraindications and Warnings

WARNINGS

  • Potential Drug Interactions

PRECAUTIONS

  • Drug Interactions
    • Inhibitors of Cytochrome P450 3A4

MEDICATION GUIDE

  • How do I use Serevent Diskus?
    • While you are using Serevent Diskus twice a day, do not use other medicines that contain a long-acting beta2-agonist or LABA for any reason...

WARNINGS

Potential Drug Interactions

Because of the potential for drug interactions and the potential for increased risk of cardiovascular adverse events, the concomitant use of Servent Diskus with strong CYP 3A4 inhibitors (e.g., ketoconazole, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) is not recommended (see CLINICAL PHARMACOLOGY: Pharmacokinetics: Drug Interactions).
    
-
-
-
-
-